METASTATIC NON-SMALL CELL LUNG CANCER
Clinical trials for METASTATIC NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for METASTATIC NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Targeted drug duo shows promise for hard-to-treat lung cancer
Disease control Recruiting nowThis study tests a drug called adagrasib, alone or with pembrolizumab (an immunotherapy), in people with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if the combination shrinks tumors and helps people live longer without t…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE2, PHASE3 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated May 26, 2026 11:27 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug called STC-15, either alone or combined with toripalimab, in people with advanced solid tumors or certain sarcomas (leiomyosarcoma and liposarcoma). The goal is to see if the treatment is safe and can shrink or control tumors. About 107 adults with can…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: STORM Therapeutics LTD • Aim: Disease control
Last updated May 26, 2026 11:25 UTC
-
Electric field therapy takes on advanced lung cancer in major trial
Disease control Recruiting nowThis study tests whether adding a device that delivers electric fields (TTFields) to standard immunotherapy and chemotherapy helps people with advanced lung cancer live longer or keep the cancer from growing. About 734 adults with metastatic non-small cell lung cancer who have no…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: NovoCure GmbH • Aim: Disease control
Last updated May 26, 2026 11:21 UTC
-
Radiation boost may extend life for patients with limited spread lung cancer
Disease control Recruiting nowThis study tests whether adding targeted radiation to standard maintenance therapy can help people with non-small cell lung cancer that has spread to 1-5 spots live longer. About 190 adults with stable disease after initial chemotherapy will be randomly assigned to standard thera…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Tata Memorial Hospital • Aim: Disease control
Last updated May 26, 2026 11:19 UTC
-
New hope for rare lung cancer mutation: phase 3 trial launches
Disease control Recruiting nowThis study tests a new drug called firmonertinib against two standard drugs (osimertinib or afatinib) in people with advanced lung cancer that has specific uncommon genetic changes (EGFR PACC mutations). About 480 participants who have not had prior treatment for advanced disease…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: ArriVent BioPharma, Inc. • Aim: Disease control
Last updated May 26, 2026 11:16 UTC
-
Supercharged immune cells take on advanced cancers in new trial
Disease control Recruiting nowThis study tests an experimental treatment called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has spread or stopped responding to standard therapies. OBX-115 uses a patient's own tumor-fighting immune cells (TILs) that have been modified to produc…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Obsidian Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 11:16 UTC
-
Engineered immune cells target Hard-to-Treat lung cancer in early trial
Disease control Recruiting nowThis early-phase trial tests a new treatment for people with a specific type of advanced lung cancer (FRa+ NSCLC) that has spread to the lining around the lungs. The therapy uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells, the…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated May 26, 2026 11:16 UTC
-
New hope for KRAS lung cancer: first human trial launches
Disease control Recruiting nowThis early-stage study tests a new drug called BBO-8520 in people with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C). The main goals are to check the drug's safety and see if it can shrink tumors. About 350 adults will take part, and the drug …
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated May 26, 2026 11:08 UTC
-
New drug cocktail aims to extend life in tough lung cancer
Disease control Recruiting nowThis study tests whether adding the drug Dato-DXd to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced or spreading non-small cell lung cancer that has high levels of a protein called PD-L1. About 740 adults with this type of …
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New hope for lung cancer patients: drug combo targets tumors after standard therapy fails
Disease control Recruiting nowThis study tests a new drug called Dato-DXd, given alone or with osimertinib, against standard chemotherapy in people with a specific type of advanced lung cancer (EGFR-mutated) that has worsened after osimertinib treatment. About 744 participants will be randomly assigned to one…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
Can adding chemo to a common lung cancer drug stop tumor growth?
Disease control Recruiting nowThis study looks at people with a type of advanced lung cancer that has a specific gene change (EGFR mutation). It compares the usual treatment, a pill called osimertinib, with osimertinib plus chemotherapy (carboplatin and pemetrexed). The goal is to see if the combination can k…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New drug combo aims to outperform standard lung cancer therapy
Disease control Recruiting nowThis study tests whether a new experimental drug (PF-08634404) combined with chemotherapy works better than the current standard treatment (pembrolizumab plus chemo) for adults with advanced non-small cell lung cancer that has spread. About 1,410 participants will be randomly ass…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
Could less be more? new study tests lower cancer drug doses to cut side effects
Disease control Recruiting nowThis study tests whether giving a lower, less frequent dose of the cancer drug atezolizumab can still control tumors while causing fewer side effects. About 30 adults with advanced lung, liver, skin, or sarcoma cancers will receive the drug alone or with other treatments. Researc…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 18, 2026 12:13 UTC
-
Gentler chemo combo aims to keep older lung cancer patients on treatment longer
Disease control Recruiting nowThis study is for adults aged 70 or older, or those who are frail, with advanced non-small cell lung cancer that has a low PD-L1 score. The goal is to see if using a reduced dose of chemotherapy together with an immunotherapy drug (anti-PD-1) causes fewer side effects that force …
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated May 18, 2026 12:07 UTC
-
Could your own immune cells beat back lung cancer?
Disease control Recruiting nowThis study tests a new treatment called LN-145, which uses immune cells taken from a patient's own tumor to fight metastatic non-small-cell lung cancer. About 170 adults with stage IV lung cancer that has spread will receive these specially grown cells. The goal is to see if this…
Matched conditions: METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated May 18, 2026 12:01 UTC